In the News
CAP accreditation of Epic Sciences lab.
San Diego, GenomeWeb — Epic Sciences has received accreditation from the College of American Pathologists (CAP). The CAP Laboratory Accreditation Program is recognized by the United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.
Xconomy — Article in Xconomy, by Murali Prahalad, Ph.D., president and CEO of Epic Sciences, looks forward, into oncology's future. The article discusses the intra- and inter- tumor diversity that is often found in cancer patients and what understanding this heterogeneity could mean for treatment.
Unbiased CTC detection and analysis from Epic Sciences.
San Diego, Epic Sciences — The Epic Sciences platform technology is designed to find CTCs from a tube of blood with millions of cells, is adaptable to multiple sample sources and can be customized to target a variety of different biomarkers. If you are trying to find one, we may be able to help you.
Diagnostics special report.
Rocky River, DDNews — Epic Sciences has been featured in a special report on liquid biopsy. This report discussed cancer as a heterogeneous disease and reviews sample choice in research and diagnostics.
Epic's San Diego lab gains CLIA certification.
San Diego, Epic Sciences — Epic Sciences has received its Clinical Laboratory Improvement Amendments (CLIA) license from the Centers for Medicare and Medicaid Services and the State of California for its circulating tumor cell lab in San Diego to advance new cancer diagnostics.
Epic's CSO, Dena Marinucci, named to PharmaVOICE 100.
PharmaVOICE — PharmaVOICE has named Dena Marinucci, Ph.D. CSO of Epic Sciences, to the magazine's 2015 list of 100 outstanding professionals in the life-sciences industry. Dena was chosen as part of the group of visionary entrepreneurs who recognized an opportunity to fill an industry need and are successfully leading their companies to new heights.
GenomeWeb: Epic Sciences collaborators share data at AACR on single cancer cell analysis, CTC biomarker detection.
New York, GenomeWeb — GenomeWeb reported from the annual meeting of the American Association for Cancer Research (AACR), where several research groups presented studies using Epic Science's no cell left behind™ platform for detecting and analyzing circulating tumor cells (CTCs).